You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Prostate Cancer Detection Through Urine Headspace Analysis Using Colorimetric Sen

    SBC: ISENSE MEDICAL CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): In the U.S., prostate cancer is the second leading cause of cancer death in men, and one in six men will eventually develop prostate cancer during his lifetime. Currently, the prostate specific antigen test and digitalrectal examination are the most predominant used tools for prostate cancer detection, but both methods have low specificity and poorly predict t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Intravesical Chitosan IL-12 Therapy in an Orthotopic Mouse Bladder Cancer Model

    SBC: SCION CARDIO-VASCULAR, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This SBIR project brings together the skills and resources of laboratories at Scion Cardio-Vascular Inc. (Scion C-V), Loma Linda University, and North Carolina State University to advance a new signaling molecule treatment for superficial bladder cancer. This treatment delivers the cytokine Interleukin 12 (IL-12) to the bladder wall using Scion C-V's muco ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Peptide-Derived Orally-Active Kappa-Opioid Receptor Agonists for Peripheral Pain

    SBC: HALIMED PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Treatment of peripheral pain of various origins remains a major unmet medical need, affecting tens to hundreds of millions of people nationwide at some time during their lives. Kappa-opioid agonists have been shown in peripheral pain models to be particularly efficacious but suffer from centrally mediated effects that have limited their development. Perhaps the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation

    SBC: ASSUAGE PHARMACEUTICALS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Smoking remains the number one avoidable cause of death in the United States. Current therapies including nicotine replacement, inhibition of the dopamine system with bupropion, and partial activation of the 4 2 neuronal nicotinic acetylcholine receptor (nAChR) with varenicline have not been particularly effective, with relapse rates at nearly 80% regardless of ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Individualized Signal Processing Strategy to Reduce Hearing Health Care Cost/Disp

    SBC: SECURBORATION, INC.            Topic: NIDCD

    This project describes a novel approach to automate and individualize the signal processing strategy for hearing aids that can result in improved speech intelligibility in background noise, greater user satisfaction and acceptance for hearing aids, and reduce barriers to affordable hearing health care. The proposed Individualized Signal Processing Strategy (ISPS) is based upon individual performan ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Engineered Neurotensin Fragments Targeting Neuropathic Pain

    SBC: JT Pharmaceuticals, Inc.            Topic: NIDCR

    DESCRIPTION (provided by applicant): Neuropathic pain management is a major unmet clinical need. Classically used medications, including opioids and non-opioids (primarily NSAIDs), have major side effects associated with their use, and many individuals donot respond to any medications. Neuropathic pain drugs with novel mechanisms of action are being sought as an alternative; however, the only succ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A novel biomaterial-based therapy to prevent type 1 diabetes

    SBC: ONEVAX, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Immune-mediated diseases such as type 1 diabetes (T1D), multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosis are reaching epidemic proportions in the US. T1D affects an estimated 3 million Americans, with more than 30,000 new patients diagnosed annually, resulting in roughly 15B in health care costs in the US each year. T1D is an autoimmu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a lasmiditan analogue for treatment of acute kidney injury

    SBC: Mitohealth, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a safe and efficacious therapeutic small molecule for treatment of acute kidney injury (AKI). AKI results from diverse insults such as sepsis, ischemia-reperfusion (I/R)or nephrotoxicant exposure and nearly half of those who develop AKI do not survive. Since treatment remains largely palliative and survival rates ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Next-generation PERG devices and methods

    SBC: JORVEC CORP.            Topic: NEI

    DESCRIPTION (provided by applicant): Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeuticapproaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroret ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Investigation of PEGylated BA-210 for RGC neuroprotection

    SBC: BIOAXONE BIOSCIENCES, INC.            Topic: NEI

    Project summary Inhibitors of Rho GTPase are neuroprotective for retinal ganglion cell (RGCs) and may be effective in treating eye diseases such as glaucoma. RGC death in glaucoma is associated with RGC axonal loss. Once neurons lose connections, normal circuitry is affected, and the loss of target-derived signals contributes to cell death. Such loss of signals may be dendritic or axonal, and prev ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government